Biomedical Engineering Reference
In-Depth Information
Grabowski H, Vernon J (1992) Brand loyalty, entry, and price competition in pharmaceuticals after
the 1984 Drug Act. J Law Econ 35
Grabowski HG, Wang YR (2006) The quantity and quality of worldwide new drug introductions:
1982-2003. Health Aff 25(2):452-460
Green PE, Rao VR (1971) Conjoint measurement for quantifying judgmental data. J Mark Res
8(3):355-363
Gregson N, Sparrowhawk K, Mauskopf J, Paul J (2005) Pricing medicines: theory and practice,
challenges and opportunities. Nat Rev 4:121-130
Grewal R, Chakravarty A, Ding M, Liechty J (2008) Counting chickens before the eggs hatch:
associating new product development portfolios with shareholder expectations in the pharma-
ceutical sector. Int J Res Mark 25(4):261-272
Gupta SD, Jain C, Sawhney MS (1999) Modeling the evolution of markets with indirect network
externalities: an application to digital television. Mark Sci 18(3):396-416
Hahn M, Park S, Krishnamurthi L, Zoltners AA (1994) Analysis of new product diffusion using a
four-segment trial-repeat model. Mark Sci 13(3):224-247
Hardie BGS, Fader PS, Wisniewski M (1998) An empirical comparison of new product trial fore-
casting models. J Forecast 17:209-229
Hariharan VG, Landsman V, Stremersch S (2013) The international growth of generic pharmaceu-
ticals: The interplay of regulation, shares and prices, working paper
Hauser JR, Toubia O (2005) The impact of utility balance and endogeneity in conjoint analysis.
Mark Sci 24(3):498-507
Helsen K, Jedidi K, DeSarbo WS (1993) A new approach to country segmentation utilizing
multinational diffusion patterns. J Mark 57(4):60-71
Iizuka T, Jin GZ (2005) The effect of prescription drug advertising on doctor visits. J Econ Manag
Strategy 14(3):701-727
Islam T, Meade N (1997) The diffusion of successive generations of a technology: a more general
model. Technol Forecast Soc Change 56(1):49-60
Islam T, Meade N (2000) Modelling diffusion and replacement. Eur J Oper Res 125(3):551-570
Jack A (2011) Medicine approvals slump to lowest in decade. Financial Times, 26 June 2011
Kalish S (1985) A new product adoption model with price, advertising, and uncertainty. Manag Sci
31(12):1569-1585
Kamakura W, Kossar B, Wedel M (2004) Identifying innovators for the cross-selling of new prod-
ucts. Manag Sci 50(8):1120-1133
Kappe E, Stremersch S (2013) Pharmaceutical sales message content. Working paper
Kappe E, Stremersch S, Venkataraman S (2013) Bucking the trend in pharmaceutical detailing:
Enriching data to gauge a policy shift. John D.C. Little Festschrift, forthcoming
Kellett N, West F, Finlay AY (2006) Conjoint analysis: a novel, rigorous tool for determining
patient preferences for topical antibiotic treatment for acne; randomized controlled trial. Br
J Dermatol 154:524-532
Kim N, Bridges E, Srivastava R (1999) A simultaneous model for innovative product category
sales diffusion and competitive dynamics. Int J Res Mark 16(2):95-111
Koch-Laking A, Park MK, Tweed EM (2010) Does DTC advertising affect physician prescribing
habits? J Fam Pract 59(11):649-650
Kolsarici C, Vakratsas D (2010) Category versus brand-level advertising messages in a highly
regulated environment. J Mark Res 47(6):1078-1089
Kontzalis P (1992) Identification of key attributes, gap analysis and simulation technique in fore-
casting market potential of ethical pharmaceutical products. Int J Forecast 8:243-249
Kremer STM, Bijmolt TMA, Leeflang PSH, Wieringa JE (2008) Generalizations on the effective-
ness of pharmaceutical promotional expenditures. Int J Res Mark 25(4):234-246
Krishnan T, Bass F, Jain D (1999) Optimal pricing strategy for new products. Manag Sci
45(12):1650-1663
Kruijshaar ME, Essink-Bot M, Donkers B, Looman CWN, Siersema PD, Steyerberg EW (2009) A
labeled discrete choice experiment adds realism to the choices presented: preferences for sur-
veillance tests for Barrett esophagus. BMC Med Res Methodol 9:31
Search WWH ::
Custom Search